All news

Barclays keeps Buy rating on Collegium Pharmaceutical

Alpha Vantage · Moomoo · · AI-summarised by FinFlash

Barclays reiterated its Buy rating on Collegium Pharmaceutical (COLL.US) and kept its target price at $48, signalling continued confidence in the stock's performance. The repeat call leaves the brokerage's view unchanged rather than reflecting a new upgrade. For investors, the maintained target implies Barclays still sees upside in Collegium shares.

Read original source

COLL company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.